Aurélie Brunet

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to <scp>PCSK</scp>9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

Catherine Lunven, Tobias Paehler, Franck Poitiers et al. · Cardiovascular Therapeutics · 2014 · 60 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study

Stephen R. Daniels, Sonia Caprio, Umesh Chaudhari et al. · Journal of clinical lipidology · 2020 · 57 citations

Medicine, Pharmacology, Pharmacotherapy +17

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Jacques Rey, Franck Poitiers, Tobias Paehler et al. · Journal of the American Heart Association · 2016 · 42 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

Jean-Marie Martinez, Aurélie Brunet, Fabrice Hurbin et al. · Clinical Pharmacokinetics · 2018 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies

Nassim Djebli, Jean-Marie Martinez, Laura Lohan et al. · Clinical Pharmacokinetics · 2017 · 26 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17